Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.

Metabolomics : Official journal of the Metabolomic Society

Kantae V, Krekels EHJ, Esdonk MJV, Lindenburg P, Harms AC, Knibbe CAJ, Van der Graaf PH, Hankemeier T.
PMID: 28058041
Metabolomics. 2017;13(1):9. doi: 10.1007/s11306-016-1143-1. Epub 2016 Dec 19.

Personalized medicine, in modern drug therapy, aims at a tailored drug treatment accounting for inter-individual variations in drug pharmacology to treat individuals effectively and safely. The inter-individual variability in drug response upon drug administration is caused by the interplay...

Cite
Kantae V, Krekels EHJ, Esdonk MJV, et al. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics. 2016;13(1):9doi: 10.1007/s11306-016-1143-1.
Kantae, V., Krekels, E. H. J., Esdonk, M. J. V., Lindenburg, P., Harms, A. C., Knibbe, C. A. J., Van der Graaf, P. H., & Hankemeier, T. (2017). Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics : Official journal of the Metabolomic Society, 13(1), 9. https://doi.org/10.1007/s11306-016-1143-1
Kantae, Vasudev, et al. "Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy." Metabolomics : Official journal of the Metabolomic Society vol. 13,1 (2017): 9. doi: https://doi.org/10.1007/s11306-016-1143-1
Kantae V, Krekels EHJ, Esdonk MJV, Lindenburg P, Harms AC, Knibbe CAJ, Van der Graaf PH, Hankemeier T. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics. 2017;13(1):9. doi: 10.1007/s11306-016-1143-1. Epub 2016 Dec 19. PMID: 28058041; PMCID: PMC5165030.
Copy Download .nbib Format: NLM
Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice.

Pulmonary circulation

Michaličková D, Jansa P, Bursová M, Hložek T, Čabala R, Hartinger JM, Ambrož D, Aschermann M, Lindner J, Linhart A, Slanař O, Krekels EHJ.
PMID: 32095231
Pulm Circ. 2020 Feb 10;10(1):2045894019898031. doi: 10.1177/2045894019898031. eCollection 2020.

Pharmacokinetic data for riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) have previously been reported from randomized clinical trials, which may not fully reflect the population encountered in routine practice. The aim of the current study was to...

Cite
Michaličková D, Jansa P, Bursová M, et al. Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice. Pulm Circ. 2020;10(1):2045894019898031doi: 10.1177/2045894019898031.
Michaličková, D., Jansa, P., Bursová, M., Hložek, T., Čabala, R., Hartinger, J. M., Ambrož, D., Aschermann, M., Lindner, J., Linhart, A., Slanař, O., & Krekels, E. H. J. (2020). Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice. Pulmonary circulation, 10(1), 2045894019898031. https://doi.org/10.1177/2045894019898031
Michaličková, Danica, et al. "Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice." Pulmonary circulation vol. 10,1 (2020): 2045894019898031. doi: https://doi.org/10.1177/2045894019898031
Michaličková D, Jansa P, Bursová M, Hložek T, Čabala R, Hartinger JM, Ambrož D, Aschermann M, Lindner J, Linhart A, Slanař O, Krekels EHJ. Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice. Pulm Circ. 2020 Feb 10;10(1):2045894019898031. doi: 10.1177/2045894019898031. eCollection 2020. PMID: 32095231; PMCID: PMC7011339.
Copy Download .nbib Format: NLM
Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis.

Pharmaceutical research

Upadhyay PJ, Vet NJ, Goulooze SC, Krekels EHJ, de Wildt SN, Knibbe CAJ.
PMID: 34664207
Pharm Res. 2021 Oct;38(10):1711-1720. doi: 10.1007/s11095-021-03113-w. Epub 2021 Oct 18.

AIM: In critically ill mechanically ventilated children, midazolam is used first line for sedation, however its exact sedative effects have been difficult to quantify. In this analysis, we use parametric time-to-event (PTTE) analysis to quantify the effects of midazolam...

Cite
Upadhyay PJ, Vet NJ, Goulooze SC, et al. Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis. Pharm Res. 2021;38(10):1711-1720doi: 10.1007/s11095-021-03113-w.
Upadhyay, P. J., Vet, N. J., Goulooze, S. C., Krekels, E. H. J., de Wildt, S. N., & Knibbe, C. A. J. (2021). Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis. Pharmaceutical research, 38(10), 1711-1720. https://doi.org/10.1007/s11095-021-03113-w
Upadhyay, Parth J, et al. "Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis." Pharmaceutical research vol. 38,10 (2021): 1711-1720. doi: https://doi.org/10.1007/s11095-021-03113-w
Upadhyay PJ, Vet NJ, Goulooze SC, Krekels EHJ, de Wildt SN, Knibbe CAJ. Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis. Pharm Res. 2021 Oct;38(10):1711-1720. doi: 10.1007/s11095-021-03113-w. Epub 2021 Oct 18. PMID: 34664207; PMCID: PMC8523120.
Copy Download .nbib Format: NLM
Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy.

European journal of clinical pharmacology

Michaličková D, Hartinger JM, Hladinová Z, Bednářová V, Szonowská B, Polakovič V, Matthios A, Tesař V, Slanař O, Krekels EHJ.
PMID: 34528123
Eur J Clin Pharmacol. 2021 Sep 16; doi: 10.1007/s00228-021-03220-y. Epub 2021 Sep 16.

No abstract available.

Cite
Michaličková D, Hartinger JM, Hladinová Z, et al. Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2021;doi: 10.1007/s00228-021-03220-y.
Michaličková, D., Hartinger, J. M., Hladinová, Z., Bednářová, V., Szonowská, B., Polakovič, V., Matthios, A., Tesař, V., Slanař, O., & Krekels, E. H. J. (2021). Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy. European journal of clinical pharmacology, . https://doi.org/10.1007/s00228-021-03220-y
Michaličková, Danica, et al. "Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy." European journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1007/s00228-021-03220-y
Michaličková D, Hartinger JM, Hladinová Z, Bednářová V, Szonowská B, Polakovič V, Matthios A, Tesař V, Slanař O, Krekels EHJ. Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2021 Sep 16; doi: 10.1007/s00228-021-03220-y. Epub 2021 Sep 16. PMID: 34528123.
Copy Download .nbib Format: NLM
From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine.

CPT: pharmacometrics & systems pharmacology

Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CA.
PMID: 23887364
CPT Pharmacometrics Syst Pharmacol. 2012 Oct 03;1:e9. doi: 10.1038/psp.2012.11.

New approaches to expedite the development of safe and effective pediatric dosing regimens and first-in-child doses are urgently needed. Model-based approaches require quantitative functions on the maturation of different metabolic pathways. In this study, we directly incorporated a pediatric...

Cite
Krekels EH, Neely M, Panoilia E, et al. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012;1:e9doi: 10.1038/psp.2012.11.
Krekels, E. H., Neely, M., Panoilia, E., Tibboel, D., Capparelli, E., Danhof, M., Mirochnick, M., & Knibbe, C. A. (2012). From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine. CPT: pharmacometrics & systems pharmacology, 1e9. https://doi.org/10.1038/psp.2012.11
Krekels, E H J, et al. "From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine." CPT: pharmacometrics & systems pharmacology vol. 1 (2012): e9. doi: https://doi.org/10.1038/psp.2012.11
Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CA. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012 Oct 03;1:e9. doi: 10.1038/psp.2012.11. PMID: 23887364; PMCID: PMC3603431.
Copy Download .nbib Format: NLM
Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy.

European journal of clinical pharmacology

Michaličková D, Hartinger JM, Hladinová Z, Bednářová V, Szonowská B, Polakovič V, Matthios A, Tesař V, Slanař O, Krekels EHJ.
PMID: 34414464
Eur J Clin Pharmacol. 2021 Aug 19; doi: 10.1007/s00228-021-03201-1. Epub 2021 Aug 19.

PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing...

Cite
Michaličková D, Hartinger JM, Hladinová Z, et al. Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2021;doi: 10.1007/s00228-021-03201-1.
Michaličková, D., Hartinger, J. M., Hladinová, Z., Bednářová, V., Szonowská, B., Polakovič, V., Matthios, A., Tesař, V., Slanař, O., & Krekels, E. H. J. (2021). Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. European journal of clinical pharmacology, . https://doi.org/10.1007/s00228-021-03201-1
Michaličková, Danica, et al. "Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy." European journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1007/s00228-021-03201-1
Michaličková D, Hartinger JM, Hladinová Z, Bednářová V, Szonowská B, Polakovič V, Matthios A, Tesař V, Slanař O, Krekels EHJ. Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2021 Aug 19; doi: 10.1007/s00228-021-03201-1. Epub 2021 Aug 19. PMID: 34414464.
Copy Download .nbib Format: NLM
Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults.

Obesity (Silver Spring, Md.)

Jurado-Fasoli L, Di X, Kohler I, Osuna-Prieto FJ, Hankemeier T, Krekels E, Harms AC, Yang W, Garcia-Lario JV, Fernández-Veledo S, Ruiz JR, Rensen PCN, Martinez-Tellez B.
PMID: 34898010
Obesity (Silver Spring). 2022 Jan;30(1):50-61. doi: 10.1002/oby.23282. Epub 2021 Dec 12.

OBJECTIVE: Omega-6 and omega-3 oxylipins are known to play a role in inflammation and cardiometabolic diseases in preclinical models. The associations between plasma levels of omega-6 and omega-3 polyunsaturated fatty acid-derived oxylipins and body composition and cardiometabolic risk factors...

Cite
Jurado-Fasoli L, Di X, Kohler I, et al. Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. Obesity (Silver Spring). 2021;30(1):50-61doi: 10.1002/oby.23282.
Jurado-Fasoli, L., Di, X., Kohler, I., Osuna-Prieto, F. J., Hankemeier, T., Krekels, E., Harms, A. C., Yang, W., Garcia-Lario, J. V., Fernández-Veledo, S., Ruiz, J. R., Rensen, P. C. N., & Martinez-Tellez, B. (2022). Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. Obesity (Silver Spring, Md.), 30(1), 50-61. https://doi.org/10.1002/oby.23282
Jurado-Fasoli, Lucas, et al. "Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults." Obesity (Silver Spring, Md.) vol. 30,1 (2022): 50-61. doi: https://doi.org/10.1002/oby.23282
Jurado-Fasoli L, Di X, Kohler I, Osuna-Prieto FJ, Hankemeier T, Krekels E, Harms AC, Yang W, Garcia-Lario JV, Fernández-Veledo S, Ruiz JR, Rensen PCN, Martinez-Tellez B. Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. Obesity (Silver Spring). 2022 Jan;30(1):50-61. doi: 10.1002/oby.23282. Epub 2021 Dec 12. PMID: 34898010.
Copy Download .nbib Format: NLM
An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables.

Expert opinion on drug metabolism & toxicology

van Rongen A, Krekels EH, Calvier EA, de Wildt SN, Vermeulen A, Knibbe CA.
PMID: 35018879
Expert Opin Drug Metab Toxicol. 2022 Jan 12; doi: 10.1080/17425255.2021.2027907. Epub 2022 Jan 12.

INTRODUCTION: When pediatric data are not available for a drug, allometric and other methods are applied to scale drug clearance across the pediatric age-range from adult values. This is applied when designing first-in-child studies, but also for off-label drug...

Cite
van Rongen A, Krekels EH, Calvier EA, et al. An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables. Expert Opin Drug Metab Toxicol. 2022;doi: 10.1080/17425255.2021.2027907.
van Rongen, A., Krekels, E. H., Calvier, E. A., de Wildt, S. N., Vermeulen, A., & Knibbe, C. A. (2022). An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables. Expert opinion on drug metabolism & toxicology, . https://doi.org/10.1080/17425255.2021.2027907
van Rongen, Anne, et al. "An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables." Expert opinion on drug metabolism & toxicology vol. (2022). doi: https://doi.org/10.1080/17425255.2021.2027907
van Rongen A, Krekels EH, Calvier EA, de Wildt SN, Vermeulen A, Knibbe CA. An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables. Expert Opin Drug Metab Toxicol. 2022 Jan 12; doi: 10.1080/17425255.2021.2027907. Epub 2022 Jan 12. PMID: 35018879.
Copy Download .nbib Format: NLM
Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy.

European journal of clinical pharmacology

Michaličková D, Hartinger JM, Hladinová Z, Bednářová V, Szonowská B, Polakovič V, Matthios A, Tesař V, Slanař O, Krekels EHJ.
PMID: 34414464
Eur J Clin Pharmacol. 2022 Jan;78(1):89-98. doi: 10.1007/s00228-021-03201-1. Epub 2021 Aug 19.

PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing...

Cite
Michaličková D, Hartinger JM, Hladinová Z, et al. Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2021;78(1):89-98doi: 10.1007/s00228-021-03201-1.
Michaličková, D., Hartinger, J. M., Hladinová, Z., Bednářová, V., Szonowská, B., Polakovič, V., Matthios, A., Tesař, V., Slanař, O., & Krekels, E. H. J. (2022). Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. European journal of clinical pharmacology, 78(1), 89-98. https://doi.org/10.1007/s00228-021-03201-1
Michaličková, Danica, et al. "Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy." European journal of clinical pharmacology vol. 78,1 (2022): 89-98. doi: https://doi.org/10.1007/s00228-021-03201-1
Michaličková D, Hartinger JM, Hladinová Z, Bednářová V, Szonowská B, Polakovič V, Matthios A, Tesař V, Slanař O, Krekels EHJ. Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2022 Jan;78(1):89-98. doi: 10.1007/s00228-021-03201-1. Epub 2021 Aug 19. PMID: 34414464.
Copy Download .nbib Format: NLM
Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations.

Pediatric research

de Hoogd S, Goulooze SC, Valkenburg AJ, Krekels EHJ, van Dijk M, Tibboel D, Knibbe CAJ.
PMID: 33603216
Pediatr Res. 2021 Dec;90(6):1201-1206. doi: 10.1038/s41390-021-01383-z. Epub 2021 Feb 18.

BACKGROUND: Morphine is commonly used for postoperative analgesia in children. Here we studied the pharmacodynamics of morphine in children after cardiac surgery receiving protocolized morphine.METHODS: Data on morphine rescue requirements guided by validated pain scores in children (n =...

Cite
de Hoogd S, Goulooze SC, Valkenburg AJ, et al. Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. Pediatr Res. 2021;90(6):1201-1206doi: 10.1038/s41390-021-01383-z.
de Hoogd, S., Goulooze, S. C., Valkenburg, A. J., Krekels, E. H. J., van Dijk, M., Tibboel, D., & Knibbe, C. A. J. (2021). Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. Pediatric research, 90(6), 1201-1206. https://doi.org/10.1038/s41390-021-01383-z
de Hoogd, Sjoerd, et al. "Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations." Pediatric research vol. 90,6 (2021): 1201-1206. doi: https://doi.org/10.1038/s41390-021-01383-z
de Hoogd S, Goulooze SC, Valkenburg AJ, Krekels EHJ, van Dijk M, Tibboel D, Knibbe CAJ. Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. Pediatr Res. 2021 Dec;90(6):1201-1206. doi: 10.1038/s41390-021-01383-z. Epub 2021 Feb 18. PMID: 33603216.
Copy Download .nbib Format: NLM
Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults.

Obesity (Silver Spring, Md.)

Jurado-Fasoli L, Di X, Kohler I, Osuna-Prieto FJ, Hankemeier T, Krekels E, Harms AC, Yang W, Garcia-Lario JV, Fernández-Veledo S, Ruiz JR, Rensen PCN, Martinez-Tellez B.
PMID: 34898010
Obesity (Silver Spring). 2021 Dec 12; doi: 10.1002/oby.23282. Epub 2021 Dec 12.

OBJECTIVE: Omega-6 and omega-3 oxylipins are known to play a role in inflammation and cardiometabolic diseases in preclinical models. The associations between plasma levels of omega-6 and omega-3 polyunsaturated fatty acid-derived oxylipins and body composition and cardiometabolic risk factors...

Cite
Jurado-Fasoli L, Di X, Kohler I, et al. Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. Obesity (Silver Spring). 2021;doi: 10.1002/oby.23282.
Jurado-Fasoli, L., Di, X., Kohler, I., Osuna-Prieto, F. J., Hankemeier, T., Krekels, E., Harms, A. C., Yang, W., Garcia-Lario, J. V., Fernández-Veledo, S., Ruiz, J. R., Rensen, P. C. N., & Martinez-Tellez, B. (2021). Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. Obesity (Silver Spring, Md.), . https://doi.org/10.1002/oby.23282
Jurado-Fasoli, Lucas, et al. "Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults." Obesity (Silver Spring, Md.) vol. (2021). doi: https://doi.org/10.1002/oby.23282
Jurado-Fasoli L, Di X, Kohler I, Osuna-Prieto FJ, Hankemeier T, Krekels E, Harms AC, Yang W, Garcia-Lario JV, Fernández-Veledo S, Ruiz JR, Rensen PCN, Martinez-Tellez B. Omega-6 and omega-3 oxylipins as potential markers of cardiometabolic risk in young adults. Obesity (Silver Spring). 2021 Dec 12; doi: 10.1002/oby.23282. Epub 2021 Dec 12. PMID: 34898010.
Copy Download .nbib Format: NLM
From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties.

CPT: pharmacometrics & systems pharmacology

Krekels EH, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, Knibbe CA.
PMID: 23887362
CPT Pharmacometrics Syst Pharmacol. 2012 Oct 10;1:e10. doi: 10.1038/psp.2012.12.

To develop a maturation function for drug glucuronidation in children, that can be used in population and physiologically based modeling approaches, the physiological and physicochemical basis of a semiphysiological glucuronidation function for children was untangled using Simcyp. The results...

Cite
Krekels EH, Johnson TN, den Hoedt SM, et al. From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties. CPT Pharmacometrics Syst Pharmacol. 2012;1:e10doi: 10.1038/psp.2012.12.
Krekels, E. H., Johnson, T. N., den Hoedt, S. M., Rostami-Hodjegan, A., Danhof, M., Tibboel, D., & Knibbe, C. A. (2012). From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties. CPT: pharmacometrics & systems pharmacology, 1e10. https://doi.org/10.1038/psp.2012.12
Krekels, E H J, et al. "From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties." CPT: pharmacometrics & systems pharmacology vol. 1 (2012): e10. doi: https://doi.org/10.1038/psp.2012.12
Krekels EH, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, Knibbe CA. From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties. CPT Pharmacometrics Syst Pharmacol. 2012 Oct 10;1:e10. doi: 10.1038/psp.2012.12. PMID: 23887362; PMCID: PMC3603432.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries